BCIQ Profiles

Target Profile Report

Serentrix: pain relief without side effects

Serentrix is looking to improve upon an old target for pain

Serentrix is looking to revive a well-known pain target that has been largely abandoned by drug developers after antagonists against it led to side effects.

Early clinical testing by Serentrix LLC has shown that the company’s small molecule antagonists of TRPV1, which has been of commercial interest for over a decade, avoid the adverse effects that have derailed programs at large pharmas and biotechs.

Current treatments for pain include opioids, gabapentinoids and nonsteroidal anti-inflammatory drugs (NSAIDs), all of which are associated with

Read the full 804 word article

How to gain access

Continue reading with a
two-week free trial.